Cancer immunology: bench to bedside immunotherapy of cancers
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Berlin
Springer
[2015]
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | L, 485 Seiten Illustrationen, Diagramme |
| ISBN: | 9783662449455 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV042984092 | ||
| 003 | DE-604 | ||
| 005 | 20151208 | ||
| 007 | t | ||
| 008 | 151106s2015 a||| |||| 00||| eng d | ||
| 016 | 7 | |a 1056836237 |2 DE-101 | |
| 020 | |a 9783662449455 |9 978-3-662-44945-5 | ||
| 035 | |a (OCoLC)906036532 | ||
| 035 | |a (DE-599)BVBBV042984092 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-11 | ||
| 082 | 0 | |a 610 | |
| 084 | |a XH 3289 |0 (DE-625)152888:12998 |2 rvk | ||
| 245 | 1 | 0 | |a Cancer immunology |b bench to bedside immunotherapy of cancers |c Nima Rezaei, editor |
| 264 | 1 | |a Berlin |b Springer |c [2015] | |
| 264 | 4 | |c © 2015 | |
| 300 | |a L, 485 Seiten |b Illustrationen, Diagramme | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Immunologie |0 (DE-588)4026637-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Immuntherapie |0 (DE-588)4026640-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |a Aufsatzsammlung |2 gnd |9 rswk-swf | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Immunologie |0 (DE-588)4026637-0 |D s |
| 689 | 0 | 2 | |a Immuntherapie |0 (DE-588)4026640-0 |D s |
| 689 | 0 | 3 | |a Aufsatzsammlung |A f |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Rezaei, Nima |d 1976- |0 (DE-588)1065847335 |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |z 978-3-662-44946-2 |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028409477&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028409477 | ||
Datensatz im Suchindex
| _version_ | 1804175320042962944 |
|---|---|
| adam_text | CONTENTS
1 FRONTIERS IN CANCER IMMUNOTHERAPY 1
JOSEPH F. MURPHY
1.1 INTRODUCTION 1
1.2 INNATE CELLS AS INITIATORS OF THE ADAPTIVE IMMUNE RESPONSE 2
1.3 CELLULAR IMMUNOTHERAPY 2
1.4 ACTIVE AND PASSIVE IMMUNOTHERAPY 2
1.4.1 ACTIVE IMMUNOTHERAPY 3
1.4.2 NONSPECIFIC IMMUNOTHERAPY 3
1.5 STIMULATION OF RESPONSES IN VIVO 4
1.6 ADOPTIVE IMMUNOTHERAPY 5
1.7 CANCER VACCINES 6
1.7.1 DENDRITIC CELLS 8
1.7.2 PHYSICAL BARRIERS, TUMOR STROMA AND VESSELS 10
1.8 MECHANISMS OF TUMOR-INDUCED TOLERANCE/ESCAPE FROM THE
IMMUNE SYSTEM 11
1.8.1 TREG CELLS 12
1.8.2 MYELOID-DERIVED SUPPRESSOR CELLS 13
1.8.3 MACROPHAGES 13
1.9 CANDIDATES FOR IMMUNOTHERAPY IN ONCOLOGY 14
1.10 COMBINATION IMMUNOTHERAPY 14
1.10.1 CHEMOTHERAPY AND MAB 15
1.10.2 CHEMOTHERAPY AND ACTIVE SPECIFIC
IMMUNOTHERAPY 15
1.10.3 CHEMOTHERAPY AND ADOPTIVE LYMPHOCYTE
IMMUNOTHERAPY 15
1.10.4 IMMUNOTHERAPY WITH RADIATION THERAPY 16
1.11 HUMORAL IMMUNOTHERAPY 16
1.12 CONCLUDING REMARKS 17
REFERENCES 17
2 NOVEL STRATEGY OF CANCER IMMUNOTHERAPY: SPIRALING UP .... 23
LEV V. DEMIDOV, IRINA ZH. SHUBINA, AND MIKHAIL V. KISELEVSKY
2.1 INTRODUCTION 23
2.2 NATURAL KILLER CELLS: THE KEY EFFECTORS OF INNATE IMMUNITY 24
2.3 ADOPTIVE IL-2/LAK (OR CIK) THERAPY OF CANCER 26
2.4 TUMOR-INFILTRATING LYMPHOCYTES (TILS) IN CANCER
IMMUNOTHERAPY 27
XIII
HTTP://D-NB.INFO/1056836237
XIV
2.5 AUTOLOGIC VACCINES ON THE BASE OF DENDRITIC CELLS
(DC VACCINES) 29
2.6 ADVANTAGES OF COMBINED IMPLICATION OF DC VACCINES
AND ACTIVATED LYMPHOCYTES 30
2.7 SPIRAL UP 30
2.8 CONCLUDING REMARKS 31
REFERENCES 31
3 NOVEL PROGNOSTIC BIOMARKERS FOR PERSONALIZED
CANCER TREATMENT 35
IDA CONTASTA, ANNA MARIA BERGHELLA, ROBERTO LATTANZIO,
OSVALDO CICCARELLI, GIANCARLO DI GREGORIO, MAURIZIO VIZIOLI,
MARINO SILVINO, LUIGI LIBORIO LIBERATORE, LUCA NAVARRA,
GIAMPAOLO CATERINO, ANTONIO MONGELLI, VINCENZO VITTORINI,
IRMA CAMPITELLI, NUNZIA ANTONUCCI, TIZIANA DEL BEATO,
ENZO SECINARO, AND PATRIZIA PELLEGRINI
3.1 INTRODUCTION 36
3.2 PRESENTATION 37
3.3 NEW BIOMARKERS FOR THE TREATMENT OF TUMORS 37
3.4 GUIDELINES FOR THE IDENTIFICATIONS OF SUITABLE BIOMARKERS:
A HEALTHY LONGEVITY IS LINKED TO AN HEALTHY FUNCTION
OF THE IMMUNE SYSTEM. THE PATHOLOGY IS GENERATED BY
ALTERATIONS OF THIS SYSTEM 40
3.5 THE IMPORTANCE OF THE EVALUATION OF BOTH GENDERS
AS INDEPENDENT GROUPS 41
3.6 MEN AND WOMEN FOLLOW DIFFERENT STRATEGIES TO REGULATE
THE HOMEOSTASIS OF THE IMMUNE SYSTEM 41
3.6.1 VARIATIONS OF PRO- AND ANTI-INFLAMMATORY CYTOKINE
LEVELS REGULATE THE IMMUNE RESPONSE AND COULD
INFLUENCE THE HEALTHY STATE
41
3.6.2 DOUBLE PROGNOSTIC BIOMARKERS : APPROPRIATE
VARIATIONS BETWEEN PRO- AND ANTI-INFLAMMATORY
CYTOKINES ASSURE THE SUCCESS OF THE IMMUNE
RESPONSE BUT FOLLOWING
DIFFERENT GENDER
PATHWAYS 42
3.6.3 THE EFFICIENCY OF THE TREATMENT IS RELATED
TO A REESTABLISHMENT OF IL-6 PATHWAYS IN WOMEN,
AND IFN-Y PATHWAYS IN MEN 44
3.7 THE VALUATION OF THE THIOREDOXIN AND CD30 SYSTEMS
FOR THE PROGNOSTIC, DIAGNOSTIC, AND THERAPEUTIC
STRATIFICATION OF PATIENTS
44
3.7.1 TRXL/RTXL SYSTEM 46
3.7.2 THE CD30/CD30L/SCD30 SYSTEM 46
3.8 NEW DOUBLE BIOMARKERS THAT ARE PROGNOSTIC FOR PATIENT
STRATIFICATION AND FOR THE PERSONALIZED THERAPIES 47
3.9 CONCLUDING REMARKS 50
REFERENCES 50
XV
4 TUMOR ANTIGEN AND EPITOPE IDENTIFICATION FOR PRECLINICAL
AND CLINICAL EVALUATION 55
SHRADDHA S. RANE, JAIMY MARIAM SULTANA JAVAD,
AND ROBERT C. REES
4.1 INTRODUCTION 55
4.2 REVERSE IMMUNOLOGY APPROACH TO PEPTIDE IDENTIFICATION... 57
4.2.1 TARGET ANTIGEN IDENTIFICATION 58
4.2.2 IN SILICO PEPTIDE PREDICTIONS 59
4.2.3 EPITOPE VALIDATION 61
4.3 DIRECT IMMUNOLOGY APPROACH 62
4.3.1 ISOLATION OF PEPTIDE-MHC COMPLEXES 62
4.3.2 ANALYSIS AND SEQUENCING OF MHC-ASSOCIATED
PEPTIDES 62
4.4 HUMAN IMMUNOTHERAPY AGAINST TUMOR-ASSOCIATED
PEPTIDES 63
4.5 STRATEGIES TO ENHANCE THE IMMUNOGENICITY OF PEPTIDE
EPITOPES 65
4.5.1 POTENTIAL ADJUVANTS FOR BOOSTING IMMUNE
RESPONSES 66
4.5.2 TLR AGONISTS IN CANCER VACCINE TRIALS 66
4.6 FUTURE PROSPECTS 68
4.7 CONCLUDING REMARKS 69
REFERENCES 69
5 STRATEGIES TO TARGET TTOMOR IMMUNOSUPPRESSION 73
OANA DRAGHICIU, HANS W. NIJMAN, AND TOOS DAEMEN
5.1 INTRODUCTION 73
5.2 THE BALANCE IS TILTED: MECHANISMS OF TUMOR
IMMUNE ESCAPE 74
5.2.1 TOLERANCE MECHANISMS 74
5.2.2 IMMUNOSUPPRESSION MECHANISMS 75
5.3 SHIFTING THE BALANCE: STRATEGIES TO TARGET TUMOR
IMMUNOSUPPRESSION 77
5.3.1 STRATEGIES TARGETING HOMING OF EFFECTOR T CELLS ... 77
5.3.2 STRATEGIES TARGETING THE ACTIVITY
OF EFFECTOR T CELLS 79
5.4 CONCLUDING REMARKS 81
REFERENCES 82
6 OVERCOMING CANCER TOLERANCE WITH IMMUNE
CHECKPOINT BLOCKADE 87
GUY T. CLIFTON, ELIZABETH A. MITTENDORF,
AND GEORGE E. PEOPLES
6.1 INTRODUCTION 87
6.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED ANTIGEN-4 (CTLA-4):
A PARADIGM FOR IMMUNE CHECKPOINT BLOCKADE 89
6.2.1 CTLA-4 FUNCTION 89
6.2.2 PRECLINICAL DEVELOPMENT OF CTLA-4 BLOCKING
THERAPY 92
6.2.3 CTLA-4 BLOCKADE MONOTHERAPY IN MELANOMA .... 93
6.2.4 TOXICITY 97
6.2.5 IMMUNE-RELATED RESPONSE CRITERIA 98
6.2.6 CTLA-4 BLOCKADE IN CANCERS OTHER THAN
CUTANEOUS MELANOMA 98
6.2.7 CTLA-4 BLOCKADE AS COMBINATION THERAPY 100
6.3 PROGRAMMED DEATH 1 (PD-1) PATHWAY 104
6.3.1 FUNCTION 104
6.3.2 PD-1 PATHWAY IN CANCER 105
6.3.3 PD-1 BLOCKADE 106
6.3.4 PD-L1 BLOCKADE 107
6.4 COMBINATION IMMUNOTHERAPY 108
6.4.1 CTLA-4 BLOCKADE AND VACCINATION 108
6.4.2 CTLA-4 BLOCKADE AND CYTOKINE THERAPY 109
6.4.3 COMBINATION CHECKPOINT BLOCKADE 110
6.5 OTHER CHECKPOINT PATHWAYS UNDER DEVELOPMENT 110
6.5.1 LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) 110
6.5.2 4-IBB ILL
6.5.3 OX-40 112
6.5.4 GLUCOCORTICOID-LNDUCED TNFR RELATED PROTEIN
(GITR) 113
6.5.5 CD40 114
6.5.6 TGN1421: A CAUTIONARY TALE 115
6.6 CONCLUDING REMARKS 116
REFERENCES 116
GENE THERAPY AND VIRUS-BASED CANCER VACCINES 131
MOHAMED LABIB SALEM, KAMAL KAMAL ELSAYED GADALLA,
BURTRAM C. FIELDING, AND STEVE H. THORNE
7.1 INTRODUCTION 131
7.2 VIRAL VECTORS USED IN CANCER GENE THERAPY 132
7.2.1 RETROVIRUS VECTORS (RVVS) 132
7.2.2 POXVIRUS VECTORS (PVVS) 135
7.2.3 ADENOVIRAL VECTORS (ADVVS) 135
7.2.4 ADENO-ASSOCIATED VIRUS VECTOR (AAVVS) 136
7.2.5 HERPES SIMPLEX VIRUS
TYPE 1 VECTORS (HSVVS) 136
7.3 NON-VIRAL METHODS OF GENE DELIVERY 137
7.3.1 DELIVERY OF PLASMID DNA 137
7.4 CANCER GENE THERAPY 138
7.4.1 ONCOGENE AND TUMOR SUPPRESSOR GENE
TARGETED GENE THERAPY 138
7.4.2 ENHANCING PRO-DRUG CYTOTOXICITY IN THE
TUMOR CELLS THROUGH GENE THERAPY 140
7.4.3 THYMIDINE KINASE (TK) 140
7.4.4 CYTOSINE DEAMINASE (CD) 141
7.5 ANTI-ANGIOGENESIS GENE THERAPY 141
7.6 CANCER VACCINES AND VACCINE PRODUCTION 141
7.6.1 VIRUS-BASED VACCINES 142
7.7 ONCOLYTIC VIRUSES 142
7.7.1 MECHANISM OF ACTION 143
7.7.2 VIRAL AGENTS USED AS ONCOLYTIC AGENTS 144
7.8 CONCLUDING REMARKS 144
REFERENCES 144
CANCER STEM CELLS: BIOLOGY AND POTENTIAL
THERAPEUTIC APPLICATIONS 151
MONICA MANGONI, MARIANGELA SOTTILI, MAURO LOI,
CHIARA GERINI, ICRO MEATTINI, AND LORENZO LIVI
8.1 INTRODUCTION 151
8.2 IDENTIFICATION AND CHARACTERIZATION OF CANCER STEM CELLS .. 152
8.2.1 SURFACE MARKERS 152
8.2.2 SIDE POPULATION 153
8.2.3 ALDEFLUOR ASSAY 153
8.2.4 SPHERE-FORMING ASSAY 154
8.2.5 SIGNALING PATHWAYS 154
8.3 A DYNAMIC CANCER STEM CELL CONCEPT 156
8.4 THE CSCS NICHE 157
8.4.1 FUNCTIONS 157
8.4.2 CSC NICHE AS THERAPEUTIC TARGET 158
8.5 CSCS IN TUMOR INVASION AND METASTASIS 158
8.5.1 CSCS, EMT, AND METASTASIS 159
8.5.2 SIGNALING PATHWAYS INVOLVED IN METASTASIS 159
8.5.3 PREMETASTATIC NICHE 161
8.6 TRACKING CSCS 161
8.7 CSC RESISTANCE: CLINICAL IMPLICATIONS 163
8.7.1 ENHANCED DNA REPAIR 163
8.7.2 FREE-RADICAL SCAVENGING 164
8.7.3 QUIESCENCE 164
8.7.4 SIGNALING PATHWAYS 164
8.8 PERSPECTIVES IN RADIATION ONCOLOGY 165
8.9 CONCLUDING REMARKS 166
REFERENCES 166
IMMUNOLOGIC APPROACHES TO TARGETING CANCER STEM CELLS ... 177
QIN PAN, QIAO LI, NING NING, YINGXIN XU,
ALFRED E. CHANG, AND MAX S. WICHA
9.1 INTRODUCTION 178
9.2 ALDEFLUOR
+
/ALDH
H,GH
SERVES AS A SPECIFIC MARKER
FOR CANCER STEM CELLS IN MULTIPLE TUMOR TYPES 178
XVIII
9.3 CANCER STEM CELLS ARE RESISTANT TO CONVENTIONAL
TUMOR THERAPIES 179
9.4 INNATE IMMUNE RESPONSE TO CANCER STEM CELLS 180
9.5 CANCER STEM CELL-PRIMED T CELLS SPECIFICALLY
TARGETING CANCER STEM CELLS 181
9.6 DEVELOPMENT OF CANCER STEM CELL-SPECIFIC VACCINE IN
IMMUNOCOMPETENT HOST 182
9.7 TARGETING THE TUMOR MICROENVIRONMENT AS A STRATEGY
TO ENHANCE IMMUNOLOGICAL TARGETING OF CANCER
STEM CELLS 184
9.8 CONCLUDING REMARKS 185
REFERENCES 185
10 HEMATOPOIETIC STEM CELL TRANSPLANTATION
AND LYMPHODEPLETION FOR THE TREATMENT OF CANCER 189
KRISTEN M. BARR, JILL A. GERSHAN, AND BRYON D. JOHNSON
10.1 INTRODUCTION 189
10.2 HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) 190
10.2.1 SOURCES OF HEMATOPOIETIC STEM CELLS (HSCS) .... 190
10.2.2 AUTOLOGOUS AND ALLOGENEIC HSCT 190
10.2.3 GRAFT-VERSUS-HOST DISEASE AND THE GRAFT
VERSUS TUMOR EFFECT 191
10.2.4 MYELOABLATIVE EFFECTS THAT PROMOTE THE
ELIMINATION OF HEMATOLOGIC MALIGNANCIES 193
10.2.5 NON-MYELOABLATIVE CONDITIONING 194
10.3 LYMPHODEPLETION FOR THE TREATMENT OF SOLID TUMORS 195
10.3.1 LYMPHODEPLETION-INDUCED
T CELL THYMOPOIESIS IS IMPORTANT FOR
RECONSTITUTION OF THE T CELL REPERTOIRE 196
10.3.2 LYMPHODEPLETION-INDUCED HOMEOSTATIC
PROLIFERATION AS STRATEGY TO AUGMENT ANTITUMOR
IMMUNITY
196
10.3.3 USE OF ANIMAL MODELS TO ADDRESS IMMUNOLOGICAL
EFFECTS OF LYMPHODEPLETION 197
10.4 CONCLUDING REMARKS 198
REFERENCES 198
11 COMBINATION OF CHEMOTHERAPY AND CYTOKINE THERAPY
IN TREATMENT OF CANCERS 203
MARIANA MALVICINI, MANGLIO M. RIZZO, LAURA ALANIZ,
AND GUILLERMO D. MAZZOLINI
11.1 INTRODUCTION 203
11.2 IMMUNE RESPONSE IN THE CONTROL OF CANCER 204
11.2.1 CANCER IMMUNOEDITING THEORY 204
11.2.2 TUMORS ESCAPE FROM THE HOST IMMUNE RESPONSE.. 205
XIX
11.3 IMMUNOTHERAPY OF CANCER 206
11.3.1 ENHANCING ANTITUMOR IMMUNITY
USING CYTOKINES 206
11.4 OVERCOMING TUMOR RESISTANCE AND THE USE
OF CHEMOTHERAPEUTIC AGENTS 207
11.4.1 CHEMOTHERAPY PLUS IMMUNOTHERAPY 208
11.4.2 RATIONALE FOR DRUG SELECTION 208
11.5 COMBINED THERAPIES 209
11.5.1 PRECLINICAL EXPERIENCE 209
11.5.2 WHAT HAVE WE LEARNED FROM THE
CLINICAL PRACTICE? 210
11.6 CONCLUDING REMARKS 212
REFERENCES 212
12 T CELL IMMUNOTHERAPY: FROM SYNTHETIC BIOLOGY
TO CLINICAL PRACTICE 217
LING ZHANG AND RIMAS J. ORENTAS
12.1 INTRODUCTION 217
12.2 T CELL RESPONSES TO CANCER 218
12.3 FROM POLYCLONAL TO SINGLE-SPECIFICITY EFFECTOR T CELLS .... 218
12.4 FROM MHC TO ANTIBODY-BASED RECOGNITION: THERAPY
WITH T CELLS EXPRESSING CARS 220
12.4.1 HISTORY OF CAR DEVELOPMENT 220
12.4.2 INCLUSION OF T CELL SIGNALING MOIETIES 220
12.4.3 VECTORS USED FOR CAR EXPRESSION 221
12.4.4 IMPACT OF T CELL CULTURE AND EXPANSION
TECHNIQUES 223
12.4.5 CLINICAL ADVANCES WITH CAR THERAPY 224
12.5 CONCLUDING REMARKS 226
REFERENCES 226
13 ROLE OF YS T LYMPHOCYTES IN CANCER IMMUNOSURVEILLANCE
AND IMMUNOTHERAPY 231
TELMA LANGA, DANIEL V. CORREIA, AND BRUNO SILVA-SANTOS
13.1 INTRODUCTION 231
13.2 TCRYS REPERTOIRES AND FUNCTIONS 232
13.2.1 MOUSE
78
T-CELL SUBSETS 233
13.2.2 HUMAN
78
T-CELL SUBSETS 233
13.3
78
T-CELL ACTIVATION: TCRYS AGONISTS 234
13.3.1 PHOSPHOAGONISTS (PHOSPHOANTIGENS) 234
13.3.2 AMINOBISPHOSPHONATES 236
13.3.3 ALKYLAMINES 236
13.3.4 PROTEIN LIGANDS 236
13.4
78
T-CELL ACTIVATION: COSTIMULATORY MOLECULES 238
13.4.1 CD27 238
13.4.2 CD28 238
13.4.3 FC RECEPTORS: CD 16 239
XX
13.5 Y6 T-CELL ACTIVATION VIA NATURAL KILLER RECEPTORS (NKRS) 240
13.5.1 NKG2D 240
13.5.2 NKG2A 243
13.5.3 NATURAL CYTOTOXICITY RECEPTORS (NCRS) 243
13.5.4 DNAM-1 244
13.6 TUMOR CELL RECOGNITION BY Y8 T CELLS: TCRS
VERSUS NKRS 244
13.7 YB T-CELL RESPONSES TO TUMORS 245
13.7.1 ANTITUMOR PROPERTIES 245
13.7.2 PRO-TUMOR PROPERTIES 247
13.8 78 T-CELL MODULATION IN CANCER CLINICAL TRIALS 248
13.9 CONCLUDING REMARKS 249
REFERENCES 252
14 ADOPTIVE T-CELL THERAPY: OPTIMIZING CHEMOKINE
RECEPTOR-MEDIATED HOMING OF T CELLS
IN CANCER IMMUNOTHERAPY 263
IMRAN SIDDIQUI, ALBERTO MANTOVANI, AND PAOLA ALLAVENA
14.1 INTRODUCTION 263
14.2 HISTORY OF ADOPTIVE IMMUNOTHERAPY OF MALIGNANCY 265
14.3 T-CELL INFILTRATION CORRELATES WITH PROGNOSIS 265
14.4 ADOPTIVE T-CELL THERAPY 266
14.5 CHALLENGES IN ADOPTIVE T-CELL THERAPY 267
14.6 CHEMOKINES 268
14.7 THE ROLE OF CHEMOKINES IN DIRECTING TISSUE TRAFFICKING
IN TUMORS 268
14.8 OVEREXPRESSION OF CHEMOKINE RECEPTORS IN ENGINEERED
LYMPHOCYTES TO BE USED FOR CANCER IMMUNOTHERAPY 271
14.9 CONCLUDING REMARKS 274
REFERENCES 275
15 B CELL REGULATION OF ANTITUMOR RESPONSE 283
AHMED A1 BAYATI. YU ZHANG, AND JOSEPH D. ROSENBLATT
15.1 INTRODUCTION 283
15.2 MECHANISMS UNDERLYING B CELL MODULATION
OF ANTITUMOR IMMUNE RESPONSE 286
15.3 B CELLS AND THE ROLE OF TREGS 286
15.4 B-REGULATORY CELL INFILTRATION INTO HUMAN TUMORS 288
15.5 BREG FUNCTION IN NON-HODGKIN LYMPHOMA 288
15.6 EFFECTS OF DEPLETION OF B CELLS ON ANTITUMOR IMMUNITY ... 289
15.7 CONCLUDING REMARKS 290
REFERENCES 290
XXI
16 MONOCLONAL ANTIBODIES FOR CANCER IMMUNOTHERAPY 293
AMIR-HASSAN ZARNANI, MAHMOOD BOZORGMEHR, MAHDI SHABANI,
LEILA BARZEGAR-YARMOHAMMADI, FATEMEH GHAEMIMANESH,
AND MAHMOOD JEDDI-TEHRANI
16.1 INTRODUCTION 294
16.2 STRUCTURAL AND FUNCTIONAL FEATURES OF ANTIBODIES 294
16.3 NATURAL ANTIBODIES IN CANCER 295
16.4 FINDING AN APPROPRIATE ANTIBODY TARGET FOR CANCER
THERAPY 296
16.4.1 CHARACTERISTICS OF A FAVORABLE CELL
SURFACE ANTIGEN 296
16.4.2 CLASSIFICATION OF CANCER ANTIGENS 296
16.4.3 TARGET IDENTIFICATION APPROACHES 296
16.5 MOLECULAR MECHANISMS INVOLVED IN MONOCLONAL
ANTIBODY-BASED THERAPY 299
16.5.1 DIRECT TUMOR CELL ELIMINATION 299
16.5.2 HARNESSING THE POTENTIAL CAPACITY OF IMMUNE
SYSTEM TO ELIMINATE TUMORS 299
16.5.3 TARGETING TUMOR STROMA AND VASCULATURE 301
16.6 ENGINEERED ANTIBODIES 302
16.6.1 MURINE MONOCLONAL ANTIBODIES 302
16.6.2 CHIMERIC AND HUMANIZED MONOCLONAL ANTIBODIES 303
16.6.3 FULLY HUMAN MONOCLONAL ANTIBODIES 303
16.6.4 ANTIBODY FRAGMENTS 304
16.6.5 BISPECIFIC ANTIBODIES (BSABS) 306
16.6.6 ANTIBODY FUSION CONSTRUCTS 307
16.6.7 IMPROVEMENT OF ANTIBODY FUNCTION 307
16.7 EVALUATION OF ANTIBODY EFFICACY 308
16.7.1 PRECLINICAL EVALUATIONS 308
16.7.2 CLINICAL EVALUATIONS 308
16.8 CLINICALLY-APPROVED MONOCLONAL ANTIBODIES 308
16.8.1 TRASTUZUMAB 309
16.8.2 BEVACIZUMAB 309
16.8.3 RITUXIMAB 310
16.8.4 THERAPEUTIC MONOCLONAL ANTIBODIES APPROVED BY
NON-FDA ORGANIZATIONS 310
16.9 MONOCLONAL ANTIBODIES CURRENTLY UNDERGOING
CLINICAL TRIALS 311
16.10 COMBINATIONAL MONOCLONAL ANTIBODY-BASED MODALITIES... 311
16.10.1 COMBINATION WITH CHEMOTHERAPY 311
16.10.2 COMBINATION WITH RADIOTHERAPY 312
16.10.3 COMBINATION WITH OTHER IMMUNOTHERAPEUTIC
METHODS 313
16.10.4 OTHER COMBINATIONAL APPROACHES 313
XXII
16.11 CURRENT LIMITATIONS IN MONOCLONAL ANTIBODY-BASED
THERAPIES 313
16.11.1 TUMORESCAPE 313
16.11.2 RELATIVELY LOW SINGLE AGENT ACTIVITY 314
16.11.3 LOW TISSUE PENETRATION 314
16.11.4 FC-FC RECEPTOR INTERACTIONS AND ASSOCIATED
LIMITATIONS 314
16.11.5 HIGH PRODUCTION COST 315
16.12 CONCLUDING REMARKS 315
REFERENCES 315
17 TOLL-LIKE RECEPTOR PATHWAY AND ITS TARGETING
IN TREATMENT OF CANCERS 329
SEYED HOSSEIN AALAEI-ANDABILI, SHAHERIN BASITH,
SANGDUN CHOI, AND NIMA REZAEI
17.1 INTRODUCTION 329
17.2 TLRS PLAY IMPORTANT ROLES IN HUMAN CARCINOGENESIS ... 330
17.3 TLR REGULATES TUMOR-INDUCED IMMUNE SYSTEM
RESPONSE 331
17.4 TLR TARGETING MAY INHIBIT CANCER CELL PROLIFERATION .... 333
17.5 TLR TRIGGERING CAN PROMOTE ANTITUMOR RESPONSE 333
17.6 REGULATORY EFFECTS OF TLRS ON PI3K/AKT SIGNALING
CONTROLLING TUMOR PROGRESSION 334
17.7 TLR-MEDIATED HYPOXIA-INDUCIBLE FACTOR 1 (HIF-1)
EXPRESSION LEADS TO TUMOR PROGRESSION 334
17.8 ROLE OF TLRS IN TUMOR CELL LYSIS AND APOPTOSIS 335
17.9 TLRS ARE INVOLVED IN TUMOR METASTASIS 335
17.10 CONCLUDING REMARKS 336
REFERENCES 337
18 RECENT ADVANCES IN THE USE OF NK CELLS AGAINST CANCER 341
AMY E. GILLGRASS, TAMARA KRNETA, AND ALI A. ASHKAR
18.1 INTRODUCTION 341
18.2 NK CELL BASICS 342
18.2.1 HOW DO NK CELLS BECOME ACTIVATED TO KILL? ... 342
18.2.2 WHY SHOULD NK CELLS BE TARGETED AS ANTICANCER
AGENTS? 343
18.3 CHALLENGES INVOLVED IN TARGETING NK CELLS 343
18.3.1 HOW MANY NK CELLS ARE IN CANCER PATIENTS
AND TUMORS? 343
18.3.2 WHAT IS THE FUNCTIONALITY OF NK CELLS
IN TUMORS? 344
18.4 CANCER IMMUNOTHERAPIES INVOLVING NK CELLS 345
18.5 ADOPTIVE NK CELL TRANSFER 346
18.5.1 HOW CAN WE PRODUCE LARGE NUMBERS
OF ACTIVATED NK CELLS? 346
XXIII
18.6 AUTOLOGOUS TRANSFER OF NK CELLS 347
18.7 ALLOGENEIC TRANSFER OF NK CELLS 348
18.8 NK CELL LINES FOR ALLOGENEIC ADOPTIVE TRANSFER 349
18.9 NK CELLS, ADCC, AND MAB THERAPY 349
18.10 CYTOKINES AND PROMOTING NK ACTIVATION/STOPPING
INHIBITION 351
18.11 CONCLUDING REMARKS 352
REFERENCES 353
19 DENDRITIC CELL VACCINES FOR CANCER THERAPY:
FUNDAMENTALS AND CLINICAL TRIALS 359
GRAZIELA GORETE ROMAGNOLI AND RAMON KANENO
19.1 INTRODUCTION 359
19.2 STRATEGIES FOR DEVELOPING CLINICAL GRADE DC VACCINES ... 361
19.3 ROUTES OF ADMINISTRATION 363
19.4 DC VACCINE FOR PROSTATIC CANCER 363
19.5 DC VACCINE FOR MELANOMA 364
19.6 DC VACCINE FOR COLORECTAL CANCER 365
19.7 DC VACCINE FOR NERVOUS TISSUE CANCER 366
19.8 CONCLUDING REMARKS 367
REFERENCES 367
20 TTIMOR-ASSOCIATED MACROPHAGES
AND CANCER DEVELOPMENT 375
KEN-ICHI ISOBE AND HENGYI XIAO
20.1 INTRODUCTION 375
20.2 CANCER AND INFLAMMATION 376
20.3 DEVELOPMENT OF MYELOID LINEAGE CELLS INCLUDING
MACROPHAGES 378
20.4 CHARACTERISTICS OF TAMS 379
20.5 REEDUCATING TAMS TO CYTOTOXIC PHENOTYPE 379
20.6 CONCLUDING REMARKS 380
REFERENCES 380
21 PHOTODYNAMIC THERAPY AND ANTITUMOR IMMUNE RESPONSE... 383
FATMA VATANSEVER AND MICHAEL R. HAMBLIN
21.1 INTRODUCTION 383
21.2 PHOTODYNAMIC THERAPY 384
21.3 CLOSER LOOK UP AT THE PDT AND TRIGGERED
IMMUNE RESPONSE 385
21.4 SIGNIFICANCE OF PDT AND ADAPTIVE IMMUNITY 387
21.5 MECHANISM OF PDT IMMUNOLOGIC EFFECTS 387
21.6 CASE STUDIES 388
21.7 CONCLUDING REMARKS 394
REFERENCES 395
XXIV
22 POLARIZATION OF T IMOR MILIEU: THERAPEUTIC IMPLICATIONS 401
STANISTAW SZALA, MAGDALENA JAROSZ-BIEJ, TOMASZ CICHORI,
RYSZARD SMOLARCZYK, AND ALEKSANDER SOCHANIK
22.1 INTRODUCTION 401
22.2 RECRUITMENT OF INFLAMMATORY CELLS BY CANCER CELLS 402
22.3 MACROPHAGE PLASTICITY: M1 AND M2 PHENOTYPES 403
22.4 TAM: CELLS WITH M2 PHENOTYPE 403
22.5 M1 -* M2 TUMOR MICROENVIRONMENT REVERSAL:
THERAPEUTIC APPROACH 405
22.6 CONCLUDING REMARKS 406
REFERENCES 406
23 IMMUNOTHERAPIES TARGETING A T IMOR-ASSOCIATED ANTIGEN,
5T4 ONCOFETAL GLYCOPROTEIN 409
PETER L. STERN
23.1 INTRODUCTION 409
23.1.1 5T4 TROPHOBLAST GLYCOPROTEIN IS
AN ONCOFETALANTIGEN 409
23.2 5T4 AND EPITHELIAL MESENCHYMAL TRANSITION (EMT) 411
23.3 5T4 MODULATION OF CHEMOKINE AND WNT SIGNALING
PATHWAYS 411
23.4 VACCINES 412
23.4.1 PRECLINICAL STUDIES 413
23.4.2 EARLY-PHASE CLINICAL TRIALS OF MVA-H5T4
(TROVAX) 413
23.4.3 TROVAX PHASE III CLINICAL TRIAL IN RCC 414
23.4.4 INSIGHTS FROM THE 5T4 KO MOUSE 415
23.4.5 IMPROVING VACCINE REGIMENS 416
23.5 5T4 ANTIBODY-TARGETED SUPERANTIGEN THERAPY 416
23.5.1 PRECLINICAL STUDIES 417
23.5.2 EARLY-PHASE CLINICAL STUDIES 417
23.5.3 A PHASE II/III CLINICAL TRIAL IN RCC 418
23.6 OTHER 5T4 ANTIBODY-TARGETED THERAPIES 418
23.6.1 ANTIBODY-DRUG CONJUGATES (ADC) 418
23.6.2 DIRECT 5T4 ANTIBODY EFFECTS 419
23.6.3 5T4 CHIMERIC ANTIGEN RECEPTORS 420
23.7 CONCLUDING REMARKS 421
REFERENCES 421
24 EMERGING BIOMARKERS DURING CLINICAL DEVELOPMENT
OF ANTI-CTLA4 ANTIBODY THERAPY 427
GEOFFERY Y. KU, CHRISANN KYI, AND JIANDA YUAN
24.1 INTRODUCTION 427
24.2 ABSOLUTE LYMPHOCYTE COUNT 428
24.3 ANALYSES OF DIFFERENT CELL POPULATIONS IN PERIPHERAL
BLOOD 429
24.3.1 T CELL ACTIVATION MARKERS 429
24.3.2 REGULATORY T CELLS 429
24.3.3 MYELOID-DERIVED SUPPRESSOR CELLS (MDSCS).... 430
XXV
24.4 ANTIGEN-SPECIFIC IMMUNOLOGICAL MONITORING 430
24.4.1 ANTIGEN-SPECIFIC ANTIBODY RESPONSE 431
24.4.2 ANTIGEN-SPECIFIC T CELL RESPONSE 431
24.5 ANALYSES OF SPECIFIC T CELL POPULATIONS IN THE TUMOR
MICROENVIRONMENT 432
24.6 FUTURE PERSPECTIVES 433
24.7 CONCLUDING REMARKS 434
REFERENCES 435
25 NEW ADVANCES IN RADIOIMMUNOTHERAPY FOR THE TREATMENT
OF CANCERS 441
FRAN?OISE KRAEBER-BODERE. CAROLINE BODET-MILIN,
CAROLINE ROUSSEAU, THOMAS CARLIER, LUDOVIC FERRER,
NICOLAS CHOUIN, FERID HADDAD, FRANCOIS DAVODEAU,
JEAN-FRANCOIS CHATAL, ALAIN FAIVRE-CHAUVET,
JEAN-FRANCOIS GESTIN, MICHEL CHEREL, AND JACQUES BARBET
25.1 INTRODUCTION 442
25.2 PRINCIPLES OF RADIOIMMUNOTHERAPY 442
25.3 RADIONUCLIDES AND RADIOLABELING TECHNIQUES
FOR THERAPY 443
25.3.1 RADIONUCLIDES 443
25.3.2 LABELING TECHNIQUES 444
25.4 THE TREATMENT OF B CELL LYMPHOMA WITH ANTI-CD20
ANTIBODIES 446
25.5 PROMISING RESULTS IN HEMOPATHIES USING
OTHER ANTIBODIES 447
25.5.1 TARGETING OF LYMPHOMA WITH ANTI-CD22
ANTIBODIES 447
25.5.2 TARGETING OF MULTIPLE MYELOMA USING
ANTI-CD 138 ANTIBODIES 448
25.6 RIT OF METASTATIC PROSTATE CANCER 449
25.7 RIT WITH ALPHA-EMITTING RADIONUCLIDES 450
25.7.1 THERAPEUTIC INDICATION 450
25.7.2 LIMITED AVAILABILITY 451
25.7.3 ISSUES AND CURRENT DEVELOPMENTS 451
25.8 HIGH EFFICACY OF PRETARGETING APPROACHES IN METASTATIC
THYROID CARCINOMA 451
25.9 IMMUNO-PET: THE FUTURE FOR DOSIMETRY ASSESSMENT
AND PATIENT SELECTION 452
25.9.1 IMMUNO-PET AND DEVELOPMENT OF NEW DRUGS... 453
25.9.2 PATIENT SELECTION FOR THERAPY 453
25.9.3 DETERMINATION OF THE CUMULATED ACTIVITY
CONCENTRATION FOR RIT 453
25.9.4 THERAPY RESPONSE 454
25.10 CONCLUDING REMARKS 454
REFERENCES 454
XXVI
26 PSYCHONEUROENDOCRINOIMMUNOTHERAPY OF CANCER 461
PAOLO LISSONI, GIUSY MESSINA, AND FRANCO ROVELLI
26.1 INTRODUCTION 461
26.2 THE PHYSIOPATHOLOGY OF ANTICANCER IMMUNITY 462
26.3 THE FUNDAMENTAL PHASES OF TUMOR ONSET
AND DISSEMINATION 463
26.4 MAIN CANCER-RELATED IMMUNONEUROENDOCRINE
ALTERATIONS 464
26.5 PRELIMINARY CLINICALLY APPLIED PNEI STRATEGIES 464
26.6 FUTURE PERSPECTIVES 465
26.7 CONCLUDING REMARKS 466
REFERENCES 466
27 ETHICAL CONSIDERATIONS IN CANCER IMMUNOTHERAPY 469
MAURIE MARKMAN
27.1 INTRODUCTION 442
27.2 ETHICAL ISSUES IN IMMUNOTHERAPY OF CANCER 470
27.3 UNIQUE TOXICITIES 470
27.4 EVALUATION OF EFFICACY IN THE CLINICAL TRIAL
AND NON-RESEARCH SETTINGS 470
27.5 ETHICAL JUSTIFICATION FOR INITIATION OF TREATMENT
IN INDIVIDUAL PATIENTS 471
27.6 CONCLUDING REMARKS 472
REFERENCES 472
INDEX 473
|
| any_adam_object | 1 |
| author2 | Rezaei, Nima 1976- |
| author2_role | edt |
| author2_variant | n r nr |
| author_GND | (DE-588)1065847335 |
| author_facet | Rezaei, Nima 1976- |
| building | Verbundindex |
| bvnumber | BV042984092 |
| classification_rvk | XH 3289 |
| ctrlnum | (OCoLC)906036532 (DE-599)BVBBV042984092 |
| dewey-full | 610 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 610 - Medicine and health |
| dewey-raw | 610 |
| dewey-search | 610 |
| dewey-sort | 3610 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01658nam a2200433 c 4500</leader><controlfield tag="001">BV042984092</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20151208 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">151106s2015 a||| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1056836237</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783662449455</subfield><subfield code="9">978-3-662-44945-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)906036532</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV042984092</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-11</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3289</subfield><subfield code="0">(DE-625)152888:12998</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cancer immunology</subfield><subfield code="b">bench to bedside immunotherapy of cancers</subfield><subfield code="c">Nima Rezaei, editor</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin</subfield><subfield code="b">Springer</subfield><subfield code="c">[2015]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">L, 485 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immunologie</subfield><subfield code="0">(DE-588)4026637-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Immunologie</subfield><subfield code="0">(DE-588)4026637-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Aufsatzsammlung</subfield><subfield code="A">f</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rezaei, Nima</subfield><subfield code="d">1976-</subfield><subfield code="0">(DE-588)1065847335</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="z">978-3-662-44946-2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028409477&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028409477</subfield></datafield></record></collection> |
| genre | Aufsatzsammlung gnd |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV042984092 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:14:24Z |
| institution | BVB |
| isbn | 9783662449455 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028409477 |
| oclc_num | 906036532 |
| open_access_boolean | |
| owner | DE-11 |
| owner_facet | DE-11 |
| physical | L, 485 Seiten Illustrationen, Diagramme |
| publishDate | 2015 |
| publishDateSearch | 2015 |
| publishDateSort | 2015 |
| publisher | Springer |
| record_format | marc |
| spelling | Cancer immunology bench to bedside immunotherapy of cancers Nima Rezaei, editor Berlin Springer [2015] © 2015 L, 485 Seiten Illustrationen, Diagramme txt rdacontent n rdamedia nc rdacarrier Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Immunologie (DE-588)4026637-0 gnd rswk-swf Immuntherapie (DE-588)4026640-0 gnd rswk-swf Aufsatzsammlung gnd rswk-swf Krebs Medizin (DE-588)4073781-0 s Immunologie (DE-588)4026637-0 s Immuntherapie (DE-588)4026640-0 s Aufsatzsammlung f DE-604 Rezaei, Nima 1976- (DE-588)1065847335 edt Erscheint auch als Online-Ausgabe 978-3-662-44946-2 DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028409477&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Cancer immunology bench to bedside immunotherapy of cancers Krebs Medizin (DE-588)4073781-0 gnd Immunologie (DE-588)4026637-0 gnd Immuntherapie (DE-588)4026640-0 gnd |
| subject_GND | (DE-588)4073781-0 (DE-588)4026637-0 (DE-588)4026640-0 |
| title | Cancer immunology bench to bedside immunotherapy of cancers |
| title_auth | Cancer immunology bench to bedside immunotherapy of cancers |
| title_exact_search | Cancer immunology bench to bedside immunotherapy of cancers |
| title_full | Cancer immunology bench to bedside immunotherapy of cancers Nima Rezaei, editor |
| title_fullStr | Cancer immunology bench to bedside immunotherapy of cancers Nima Rezaei, editor |
| title_full_unstemmed | Cancer immunology bench to bedside immunotherapy of cancers Nima Rezaei, editor |
| title_short | Cancer immunology |
| title_sort | cancer immunology bench to bedside immunotherapy of cancers |
| title_sub | bench to bedside immunotherapy of cancers |
| topic | Krebs Medizin (DE-588)4073781-0 gnd Immunologie (DE-588)4026637-0 gnd Immuntherapie (DE-588)4026640-0 gnd |
| topic_facet | Krebs Medizin Immunologie Immuntherapie Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028409477&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT rezaeinima cancerimmunologybenchtobedsideimmunotherapyofcancers |